Compare Vanguard Total Bond Market Index Fund ETF (BND) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs McKesson Corporation — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation pays a 0.43% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and McKesson Corporation is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | MCK | |
|---|---|---|
52-Week High | $75.17 | $995.69 |
52-Week Low | $72.15 | $659.01 |
Market Cap | — | $102.58B |
Sector | — | Health |
Enterprise Value | — | $109.12B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.4, up 0.21% today, with a neutral technical signal from indicators like RSI near 50. Recent news highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, August 5, 2026), while Arkadios Wealth increased holdings by 41.9% (SEC filing, July 30, 2026). The bond ETF faces headwinds from rising Treasury yields and inflation concerns, as noted in financial media.
Outlook is cautious due to interest rate sensitivity and macroeconomic volatility. Risks include Fed policy shifts and oil price fluctuations, but BND offers diversification and steady dividends, with recent payouts around $0.24-$0.25. Investors should weigh income benefits against bond market pressures.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
